Lidbree

Lidocaine, the active ingredient in Lidbree, is a local anesthetic presented as a solution for intracervical and intrauterine use. It provides rapid, reversible loss of sensation in the cervix and uterine cavity, facilitating procedures and reducing pain during early labor.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU quality standards and offers reliable logistics for global distribution. Customers benefit from consistent batch release and regulatory support. Lidbree is manufactured under strict GMP conditions.

Lidbree, a lidocaine formulation, is used in gynecologic and obstetric procedures that require local anesthesia of the cervix or uterine cavity.

- Cervical ripening: provides local anesthesia to facilitate mechanical dilation during induction of labor. - Labor analgesia: reduces pain perception during early active labor. - Hysteroscopic procedures: anesthetizes the uterine cavity to improve patient comfort during diagnostic or operative hysteroscopy.

Lidbree may cause a range of adverse reactions, from mild to severe, depending on the site of administration and patient sensitivity.

Common Side Effects: - Burning or stinging at the injection site - Mild itching or rash - Transient dizziness or light‑headedness - Nausea or mild vomiting - Headache - Transient hypotension

Serious or Rare Side Effects: - Allergic reaction including angio‑edema or anaphylaxis - Seizures or convulsions - Cardiac arrhythmias such as ventricular tachycardia - Methemoglobinemia - Respiratory depression - Persistent numbness beyond expected duration

When using Lidbree, clinicians should observe several precautionary measures to minimise risks.

- Allergy assessment: confirm no known hypersensitivity to lidocaine or other amide‑type anesthetics - Dose minimisation: use the lowest effective volume for the intended procedure - Cardiovascular monitoring: observe heart rate and blood pressure during and after administration - Avoid intravascular injection: aspirate before injection to prevent systemic toxicity - Caution in hepatic impairment: reduce dose as lidocaine is metabolised by the liver - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight

Lidbree can interact with other medicines, altering its safety profile or efficacy.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiotoxicity - Other local anesthetics: additive risk of systemic toxicity - CYP1A2 or CYP3A4 inhibitors (e.g., cimetidine, erythromycin): increase plasma lidocaine levels

Moderate Interactions (Monitor Closely): - Beta‑blockers (e.g., propranolol): may enhance bradycardia - Diuretics (e.g., furosemide): may reduce plasma protein binding, raising free lidocaine - Magnesium sulfate: can augment neuromuscular blockade